AI Terminal
STRATEC SE
Report Publication Announcement • Mar 19, 2025
416_rns_2025-03-19_cd38b16b-a737-4980-b972-a40667c14f19.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 19 March 2025 16:15
STRATEC ANNOUNCES CHANGES TO 2025 FINANCIAL CALENDAR
STRATEC SE / Key word(s): Miscellaneous
STRATEC ANNOUNCES CHANGES TO 2025 FINANCIAL CALENDAR
19.03.2025 / 16:15 CET/CEST
The issuer is solely responsible for the content of this announcement.
STRATEC ANNOUNCES CHANGES TO 2025 FINANCIAL CALENDAR
Birkenfeld, March 19, 2025
STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) is today announcing a postponement in the publication date for its 2024 Annual Report. Publication is now scheduled for April 29, 2025. This postponement is to be viewed in connection with the increased time and coordination required due to the change of external auditor (initial audit), as well as with capacity bottlenecks, some of which sickness-related, in the finance department.
Prior to publication of its Annual Report, STRATEC plans to publish its preliminary results for the 2024 financial year together with its guidance for 2025. The exact date for this publication will be announced in advance. Based on current information, STRATEC expects that the targets formulated for the 2024 financial year, namely consolidated sales to remain stable or decline slightly (on a constant-currency basis) and an adjusted EBIT margin of around 10.0% to 12.0%, have been met.
Given mandatory convocation deadlines, the new publication date for the 2024 Annual Report will also make it necessary to postpone the Annual General Meeting scheduled to take place on May 23, 2025. The 2025 Annual General Meeting will now be held on June 17, 2025.
ABOUT STRATEC
STRATEC SE ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.
The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.
FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
19.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | STRATEC SE |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE000STRA555 |
| WKN: | STRA55 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2103158 |
| End of News | EQS News Service |
2103158 19.03.2025 CET/CEST